ReviewCurrent neuropharmacology2015
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics.
Review in Current neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Investigational Drugs for the Treatment of Depression (Part 1): Monoaminergic, Orexinergic, GABA-Ergic, and Anti-Inflammatory Agents.Frontiers in pharmacology · 2022Pooled it
- Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study.The international journal of neuropsychopharmacology · 2021Trial
- Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.Brain and behavior · 2020Trial
- Delayed effect of bifrontal transcranial direct current stimulation in patients with treatment-resistant depression: a pilot study.BMC psychiatry · 2019Trial
- Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder.International clinical psychopharmacology · 2019Trial
- Treating major depression with yoga: A prospective, randomized, controlled pilot trial.PloS one · 2017Trial
- Effects of ultrasound-induced stress on gut microbiota of mice.Veterinary world · 2023Article
- Dose-dependent effects of esketamine on brain activity in awake mice: A BOLD phMRI study.Pharmacology research & perspectives · 2022Article
- Clinical Thyrotoxicosis Resulting from Liothyronine Augmentation of Antidepressant Therapy in an Adolescent.Case reports in psychiatry · 2022Article
- High-frequency repetitive transcranial magnetic stimulation alleviates the cognitive side effects of electroconvulsive therapy in major depression.Frontiers in psychiatry · 2022Article
- Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study.The Psychiatric quarterly · 2021Observational
- Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders.Journal of psychiatry & neuroscience : JPN · 2021Review
- Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression: A Real-World, Prospective Study.Frontiers in psychiatry · 2021Article
- Shorter recovery times and better cognitive function-A comparative pilot study of magnetic seizure therapy and electroconvulsive therapy in patients with depressive episodes.Brain and behavior · 2020Article
- Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study.BMC psychiatry · 2020Article
- A Tellurium-Based Small Immunomodulatory Molecule Ameliorates Depression-Like Behavior in Two Distinct Rat Models.Neuromolecular medicine · 2020Article
- The Authors Respond.Journal of managed care & specialty pharmacy · 2020Article
- Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression.Journal of managed care & specialty pharmacy · 2018Observational
- The Evolutionary Theory of Depression.Medical science monitor : international medical journal of experimental and clinical research · 2017Review
- The Role of Lipid Biomarkers in Major Depression.Healthcare (Basel, Switzerland) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is associated with a significant burden and costs to the society. As remission of depressive symptoms is achieved in only one-third of the MDD patients after the first antidepressant trial, unsuccessful treatments contribute largely to the observed suffering and social costs of MDD. The present article provides a summary of the therapeutic strategies that have been tested for treatment-resistant depression (TRD). A computerized search on MedLine/PubMed database from 1975 to September 2014 was performed, using the keywords "treatment-resistant depression", "major depressive disorder", "adjunctive", "refractory" and "augmentation". From the 581 articles retrieved, two authors selected 79 papers. A manual searching further considered relevant articles of the reference lists. The evidence found supports adding or switching to another antidepressant from a different class is an effective strategy in more severe MDD after failure to an initial antidepressant trial. Also, in subjects resistant to two or more classes of antidepressants, some augmentation strategies and antidepressant combinations should be considered, although the overall response and remission rates are relatively low, except for fast acting glutamatergic modulators. The wide range of available treatments for TRD reflects the complexity of MDD, which does not underlie diverse key features of the disorder. Larger and well-designed studies applying dimensional approaches to measure efficacy and effectiveness are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.